HRP20110009T1 - Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži - Google Patents
Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži Download PDFInfo
- Publication number
- HRP20110009T1 HRP20110009T1 HR20110009T HRP20110009T HRP20110009T1 HR P20110009 T1 HRP20110009 T1 HR P20110009T1 HR 20110009 T HR20110009 T HR 20110009T HR P20110009 T HRP20110009 T HR P20110009T HR P20110009 T1 HRP20110009 T1 HR P20110009T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- compound
- salt
- benzoxazol
- aminomethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 24
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 4
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 10
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Spoj predstavljen sljedećom formulom (1) naznačen time, dasvaki od R1 i R2, koji mogu biti identični ili međusobno različiti, predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; svaki od R3a, R3b, R4a i R4b, koji mogu biti identični ili međusobno različiti, predstavlja atom vodika, atom halogena, nitro skupinu, hidroksilnu skupinu, C1-4 alkilnu skupina, trifluorometilnu skupinu, C1-4 alkoksi skupinu, C1-4 alkilkarboniloksi skupinu, di-C1-4 alkilamino skupinu, C1-4 alkilsulfoniloksi skupinu, C1-4 alkilsulfonilnu skupinu, C1-4 alkilsulfinilnu skupinu ili C1-4 alkiltio skupinu, ili R3a i R3b, ili R4a i R4b mogu biti povezani tako da tvore alkilendioksi skupinu; X predstavlja atom kisika, atom sumpora ili N-R5 (R5 predstavlja atom vodika, C1-4 alkilnu skupinu, C1-4 alkilsulfonilnu skupinu ili C1-4 alkiloksikarbonilnu skupinu); Y predstavlja atoma kisika, S(O)1 (1 je broj u rasponu od 0 do 2), karbonilnu skupinu, karbonilamino skupinu, aminokarbonilnu skupinu, sulfonilamino skupinu, aminosulfonilnu skupinu ili NH; Z predstavlja CH ili N; n je broj u rasponu od 1 do 6; a m je broj u rasponu od 2 do 6, ili njegove soli. Patent sadrži još 11 patentnih zahtjeva.
Claims (12)
1. Spoj predstavljen sljedećom formulom (1)
[image]
naznačen time, da
svaki od R1 i R2, koji mogu biti identični ili međusobno različiti, predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; svaki od R3a, R3b, R4a i R4b, koji mogu biti identični ili međusobno različiti, predstavlja atom vodika, atom halogena, nitro skupinu, hidroksilnu skupinu, C1-4 alkilnu skupina, trifluorometilnu skupinu, C1-4 alkoksi skupinu, C1-4 alkilkarboniloksi skupinu, di-C1-4 alkilamino skupinu, C1-4 alkilsulfoniloksi skupinu, C1-4 alkilsulfonilnu skupinu, C1-4 alkilsulfinilnu skupinu ili C1-4 alkiltio skupinu, ili R3a i R3b, ili R4a i R4b mogu biti povezani tako da tvore alkilendioksi skupinu; X predstavlja atom kisika, atom sumpora ili N-R5 (R5 predstavlja atom vodika, C1-4 alkilnu skupinu, C1-4 alkilsulfonilnu skupinu ili C1-4 alkiloksikarbonilnu skupinu); Y predstavlja atoma kisika, S(O)1 (1 je broj u rasponu od 0 do 2), karbonilnu skupinu, karbonilamino skupinu, aminokarbonilnu skupinu, sulfonilamino skupinu, aminosulfonilnu skupinu ili NH; Z predstavlja CH ili N; n je broj u rasponu od 1 do 6; a m je broj u rasponu od 2 do 6, ili njegove soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da X predstavlja atom kisika, Y predstavlja atom kisika, a Z predstavlja CH.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je taj spoj odabran iz skupine:
2-[3-[[N-(benzoksazol-2-il)-N-3-(4-fluorofenoksi)propil]aminometil]fenoksi] maslačna kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-2-(4-klorfenoksi)etil]aminometil]fenoksi] maslačna kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-2-(4-fluorofenoksi)etil]aminometil]fenoksi] maslačna kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-3-fenoksipropil]aminometil]fenoksi] propionska kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-3-fenoksipropil]aminometil]fenoksi] octena kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-3-fenoksipropil]aminometil]fenoksi] maslačna kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-3-(4-metoksifenoksi)propil]aminometil]fenoksi] maslačna kiselina,
2-[3-[[N-(benzoksazol-2-il)-N-3-(4-metoksifenoksi)propil]aminometil]fenoksi]propionska kiselina.
4. Lijek, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
5. Lijek za liječenje hiperlipidemije, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
6. Lijek za liječenje arterioskleroze, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
7. Lijek za liječenje dijabetesa, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
8. Lijek za liječenje komplikacija dijabetesa, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
9. Lijek za liječenje upala, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
10. Lijek za liječenje srčanih bolesti, naznačen time, da kao djelatnu tvar sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3.
11. Farmaceutski pripravak, naznačen time, da sadrži spoj ili sol tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3 i farmakološki prihvatljiv nosač.
12. Uporaba spoja ili soli tog spoja koji se navode u bilo kojem patentnom zahtjevu 1 do 3, naznačena time, da je ta uporaba proizvodnja lijeka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110009T1 true HRP20110009T1 (hr) | 2011-03-31 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110009T HRP20110009T1 (hr) | 2003-09-03 | 2011-01-07 | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (hr) |
| EP (1) | EP1661890B1 (hr) |
| JP (2) | JP4226005B2 (hr) |
| KR (1) | KR101160808B1 (hr) |
| AU (1) | AU2004270538C1 (hr) |
| BR (1) | BRPI0413991B8 (hr) |
| CA (1) | CA2535749C (hr) |
| CY (1) | CY1111867T1 (hr) |
| EA (1) | EA009374B1 (hr) |
| HK (1) | HK1093975A1 (hr) |
| HR (1) | HRP20110009T1 (hr) |
| IL (1) | IL173639A (hr) |
| MX (1) | MXPA06002435A (hr) |
| NO (1) | NO335823B1 (hr) |
| NZ (1) | NZ545692A (hr) |
| PL (1) | PL1661890T3 (hr) |
| TW (1) | TWI324599B (hr) |
| WO (1) | WO2005023777A1 (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338789T3 (es) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | Antagonistas macrociclicos del receptor de motilina. |
| EP1648922B9 (en) * | 2003-07-31 | 2013-04-03 | Tranzyme Pharma Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| PL1852426T3 (pl) | 2005-02-23 | 2014-04-30 | Kowa Co | Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego |
| EP1854779A4 (en) * | 2005-03-01 | 2010-07-21 | Kowa Co | OPTICALLY ACTIVE, PPAR-ACTIVATING COMPOSITE INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR |
| ES2342319T3 (es) * | 2005-05-31 | 2010-07-05 | Kowa Co., Ltd. | Procedimiento para la produccion de compuestos para activar ppar opticamente activos. |
| EP1908747B1 (en) | 2005-07-28 | 2012-01-04 | Kowa Company, Ltd. | Process for producing optically active 2-hydroxybutyric ester |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008094860A2 (en) * | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| EP2484361B1 (en) * | 2009-09-28 | 2015-11-11 | Kowa Company, Ltd. | Agent for reducing visceral fat weight |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases | |
| CA2901650C (en) * | 2012-09-27 | 2021-05-04 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| EP2980061A4 (en) | 2013-03-29 | 2016-09-07 | Kowa Co | PROCESS FOR IMPROVING THE OPTICAL PURITY OF 2-HYDROXYCARBOXYLIC ACID OR ITS DERIVATIVE |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| AU2014312931B2 (en) | 2013-08-28 | 2019-09-19 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| AU2015204572B2 (en) * | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| WO2017082393A1 (ja) * | 2015-11-12 | 2017-05-18 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| PT3275438T (pt) | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
| US20210069157A1 (en) * | 2016-08-25 | 2021-03-11 | Kowa Company, Ltd. | Agent for treatment of pbc |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| CN110167595A (zh) | 2017-01-11 | 2019-08-23 | 兴和株式会社 | 非酒精性脂肪性肝病的预防及治疗药 |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| EP3646865A4 (en) | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | MEDICINE |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| US20200121648A1 (en) * | 2017-06-30 | 2020-04-23 | Kowa Company, Ltd. | Pharmaceutical composition |
| EP3646866A4 (en) * | 2017-06-30 | 2021-03-24 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| EP3646863B1 (en) * | 2017-06-30 | 2024-01-03 | Kowa Company, Ltd. | Pharmaceutical composition |
| US11419854B2 (en) | 2017-06-30 | 2022-08-23 | Kowa Company, Ltd. | Medicament containing pemafibrate |
| EP3646867A4 (en) | 2017-06-30 | 2021-03-24 | Kowa Company, Ltd. | PHARMACEUTICAL COMPOSITION |
| JPWO2019004452A1 (ja) * | 2017-06-30 | 2020-04-30 | 興和株式会社 | 医薬組成物 |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| CN111741753A (zh) * | 2017-12-21 | 2020-10-02 | 兴和株式会社 | 治疗高甘油三酯血症的方法 |
| WO2019133462A1 (en) | 2017-12-27 | 2019-07-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of pemafibrate |
| US20210290598A1 (en) | 2018-05-08 | 2021-09-23 | National University Corporation Okayama University | Medicament useful for cardiovascular disease |
| JP7071538B2 (ja) | 2018-12-27 | 2022-05-19 | 興和株式会社 | 医薬組成物 |
| EP3903780A4 (en) * | 2018-12-27 | 2023-01-18 | Kowa Company, Ltd. | MEDICINAL PRODUCT |
| TW202038906A (zh) | 2018-12-27 | 2020-11-01 | 日商興和股份有限公司 | 醫藥品 |
| WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
| US20240197688A1 (en) | 2021-04-20 | 2024-06-20 | Kowa Company, Ltd. | Combination medicine for preventing/treating dyslipidemia or cardiovascular disease |
| CA3216699A1 (en) | 2021-04-28 | 2022-11-03 | Kowa Company, Ltd. | Blood carnitine-increasing agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| JPWO2002046176A1 (ja) * | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体の活性化剤 |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| EP1480957A1 (en) * | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja active Active
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en active Active
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko active IP Right Grant
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja active Application Filing
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx unknown
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en active Active
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en active Active
- 2006-12-29 HK HK06114278.8A patent/HK1093975A1/xx not_active IP Right Cessation
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-07 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110009T1 (hr) | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži | |
| AU2009200957B2 (en) | Organic compounds | |
| JP7366002B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
| RU2008116581A (ru) | Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| HRP20120829T1 (hr) | Karboksilne kiseline supstituirane fenilaminobenzoksazolom, postupak njihovog dobivanja i njihova upotreba kao medikamenata | |
| IN2015DN01132A (hr) | ||
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| RU2008134534A (ru) | 3,5-ди(арилили гетероарил)изоксазолы и 1,2,4-оксадиазолы в качестве агонистов рецентора s1p1, иммунодепрессантных и противовоспалительных агентов | |
| JP2005502600A5 (hr) | ||
| ATE416159T1 (de) | Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält | |
| JP2004536115A5 (hr) | ||
| RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
| RU2007116987A (ru) | Новые соединения | |
| JP7085686B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびそれを含む薬剤学的組成物 | |
| TW201249786A (en) | Antibacterial agents | |
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| RU2008129723A (ru) | Ингибиторы ccr9 активности | |
| TW200634001A (en) | Novel compounds | |
| CA2592367A1 (en) | Novel cyclohexane derivatives | |
| RU2006106231A (ru) | Замещенные производные диоксида тиазолбензоизотиазола, способ их получения и их применение | |
| AR083020A1 (es) | Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden | |
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| CA2581232A1 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i | |
| HRP20120344T1 (hr) | N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije | |
| CA2487727A1 (en) | Compounds useful in the treatment of anthrax and inhibiting lethal factor |